Merck & Co., Inc. (NYSE:MRK) Shares Sold by Park National Corp OH
Merck & Co., Inc. (NYSE:MRK) Shares Sold by Park National Corp OH
Park National Corp OH trimmed its stake in shares of Merck & Co., Inc. (NYSE:MRK – Get Rating) by 8.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 102,229 shares of the company's stock after selling 9,382 shares during the quarter. Park National Corp OH's holdings in Merck & Co., Inc. were worth $9,320,000 at the end of the most recent quarter.
據Park National Corp OH最近提交給美國證券交易委員會(Securities and Exchange Commission，簡稱：美國證券交易委員會)的文件顯示，該公司在第二季度減持了8.4%的默克公司股票。該機構投資者在本季度出售了9,382股後，持有該公司股票102,229股。截至最近一個季度末，Park National Corp OH持有的默克公司股份價值9,320,000美元。
Several other institutional investors and hedge funds have also recently bought and sold shares of MRK. Norges Bank acquired a new position in shares of Merck & Co., Inc. during the 4th quarter worth about $1,823,028,000. BlackRock Inc. boosted its position in shares of Merck & Co., Inc. by 5.5% during the 4th quarter. BlackRock Inc. now owns 198,224,263 shares of the company's stock worth $15,191,909,000 after acquiring an additional 10,326,974 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Merck & Co., Inc. by 12.7% during the 4th quarter. Geode Capital Management LLC now owns 48,153,283 shares of the company's stock worth $3,682,009,000 after acquiring an additional 5,409,154 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Merck & Co., Inc. by 2,671.4% during the 1st quarter. Renaissance Technologies LLC now owns 5,099,334 shares of the company's stock worth $418,400,000 after acquiring an additional 4,915,334 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Merck & Co., Inc. by 2.3% during the 1st quarter. Vanguard Group Inc. now owns 216,096,057 shares of the company's stock worth $17,730,682,000 after acquiring an additional 4,893,526 shares in the last quarter. 73.33% of the stock is owned by institutional investors and hedge funds.
其他幾家機構投資者和對衝基金最近也買賣了MRK的股票。挪威銀行在第四季度增持了價值約1,823,028,000美元的默克公司股票。貝萊德在第四季度將其在默克公司的股票持倉量提高了5.5%。貝萊德股份有限公司在上個季度增持了10,326,974股後，現在持有198,224,263股該公司股票，價值15,191,909,000美元。Geode Capital Management LLC在第四季度將其在默克公司(Merck&Co.，Inc.)的股票頭寸增加了12.7%。Geode Capital Management LLC在上個季度增持了5,409,154股後，現在擁有48,153,283股該公司股票，價值3,682,009,000美元。復興科技有限責任公司在第一季度將其在默克公司的股票頭寸增加了2,671.4%。復興科技有限責任公司在上個季度增持了4,915,334股後，現在擁有5,099,334股該公司股票，價值418,400,000美元。最後，先鋒集團(Vanguard Group Inc.)在第一季度將其在默克公司(Merck&Co.，Inc.)的股票頭寸增加了2.3%。先鋒集團目前持有216,096,057股該公司股票，價值17,730,682,000美元，上個季度又購入了4,893,526股。73.33%的股票由機構投資者和對衝基金持有。
Analyst Ratings Changes
分析師評級發生變化
Several research analysts have recently issued reports on the company. Atlantic Securities upped their price objective on Merck & Co., Inc. from $105.00 to $110.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 13th. Cowen boosted their target price on Merck & Co., Inc. from $95.00 to $102.00 and gave the company a "market perform" rating in a report on Monday, June 27th. Berenberg Bank raised Merck & Co., Inc. from a "hold" rating to a "buy" rating and boosted their target price for the company from $95.00 to $100.00 in a report on Wednesday. Cowen boosted their target price on Merck & Co., Inc. from $95.00 to $102.00 and gave the company a "market perform" rating in a report on Monday, June 27th. Finally, Daiwa Capital Markets raised Merck & Co., Inc. from a "neutral" rating to a "buy" rating and boosted their target price for the company from $89.00 to $102.00 in a report on Wednesday, July 6th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $98.28.
幾位研究分析師最近發佈了關於該公司的報告。大西洋證券在7月13日星期三的一份研究報告中將默克公司的目標價從105.00美元上調至110.00美元，並給予該股“增持”評級。考恩在6月27日週一的一份報告中將默克公司的目標價從95美元上調至102.00美元，並給予該公司“市場表現”評級。貝倫伯格銀行在週三的一份報告中將默克公司的評級從持有上調至買入，並將該公司的目標價從95美元上調至100.00美元。考恩在6月27日週一的一份報告中將默克公司的目標價從95美元上調至102.00美元，並給予該公司“市場表現”評級。最後，大和資本市場在7月6日週三的一份報告中將默克公司的評級從中性上調至買入，並將該公司的目標價從89美元上調至102.00美元。7名投資分析師對該股的評級為持有，11名分析師給出了買入評級，兩名分析師給出了強烈的買入評級。根據MarketBeat.com的數據，該股目前的平均評級為“中等買入”，平均目標價為98.28美元。
Merck & Co., Inc. Stock Performance
默克公司股票表現
Merck & Co., Inc. (NYSE:MRK – Get Rating) last issued its earnings results on Thursday, July 28th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.67 by $0.20. The business had revenue of $14.59 billion during the quarter, compared to the consensus estimate of $13.85 billion. Merck & Co., Inc. had a return on equity of 48.45% and a net margin of 29.00%. The company's revenue for the quarter was up 28.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.31 EPS. On average, equities analysts forecast that Merck & Co., Inc. will post 7.33 EPS for the current year.
默克公司(紐約證券交易所代碼：MRK-GET評級)最近一次發佈收益報告是在7月28日星期四。該公司公佈本季度每股收益(EPS)為1.87美元，高於分析師普遍預期的1.67美元和0.20美元。該業務本季度營收為145.9億美元，而市場普遍預期為138.5億美元。默克公司的股本回報率為48.45%，淨利潤率為29.00%。該公司本季度營收同比增長28.0%。去年同期，該業務的每股收益為1.31美元。股票分析師平均預測，默克公司本年度每股收益將達到7.33歐元。
Merck & Co., Inc. Announces Dividend
默克公司宣佈分紅
The company also recently declared a quarterly dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 15th will be issued a $0.69 dividend. This represents a $2.76 dividend on an annualized basis and a dividend yield of 3.15%. The ex-dividend date of this dividend is Wednesday, September 14th. Merck & Co., Inc.'s dividend payout ratio is currently 42.27%.
該公司最近還宣佈了季度股息，將於10月7日(星期五)支付。9月15日(星期四)登記在冊的投資者將獲得0.69美元的股息。這意味着年化股息為2.76美元，股息收益率為3.15%。本次股息除息日為9月14日星期三。默克公司目前的股息支付率為42.27%。
Merck & Co., Inc. Profile
默克公司簡介
(Get Rating)
(獲取評級)
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.
默克公司是一家全球性的醫療保健公司。它通過兩個部門運作，製藥和動物健康。製藥部門提供腫瘤學、醫院急性護理、免疫學、神經科學、病毒學、心血管和糖尿病等領域的人類健康藥物產品，以及疫苗產品，如預防性兒科、青少年和成人疫苗。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Merck & Co., Inc. (MRK)
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- Is There a Cure for What is Ailing Teladoc Stock?
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It's a Down Week
- 免費獲取StockNews.com關於默克公司的研究報告(MRK)
- 股市：紅海中的三座強國
- 第四季度值得考慮的3家銀行
- 有什麼辦法可以治癒Teladoc股票的問題嗎？
- MarketBeat：回顧一週9/12-9/16
- 沒有人告訴這三隻股票這是下跌的一週
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Get Rating).
想看看還有哪些對衝基金持有MRK嗎？訪問HoldingsChannel.com獲取默克公司(NYSE：MRK-GET Rating)的最新13F文件和內幕交易信息。
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
每天收到默克公司的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對默克公司和相關公司的最新新聞和分析師評級的每日簡要摘要。